Search
for
Sort by
Research 361–390 of 1000+
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
- 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
- RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
- Clinical use of 5α-reductase inhibitors
- The relevance of using 5α-reductase inhibitors in the conservative management of benign prostatic hyperplasia: A review
- Novel type 1 5a-reductase Inhibitors with Antiproliferative Potential on LNCaP cells
- Evaluation of the phenotypic, proliferative and secretory profile of mesenchymal stem cells from adipose tissue captured by laser-assisted liposuction
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- 5α- Reductase Inhibitors in Prostate Cancer: An Overview
- Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient
- New Activators and Inhibitors in the Hair Cycle Clock: Targeting Stem Cells’ State of Competence
- 5α-Reductase inhibitors in androgenetic alopecia
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Comparison of the Therapeutic Effect of Allogeneic and Xenogeneic Small Extracellular Vesicles in Soft Tissue Repair
- Enhanced skin permeation of 5α-reductase inhibitors entrapped into surface-modified liquid crystalline nanoparticles
- Synthesis and activity of 8-substituted benzo[c]quinolizin-3-ones as dual inhibitors of human 5α-reductases 1 and 2
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
- Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
- 711 Small molecule wnt pathway inhibitor (SM04755) as a potential topical psoriasis treatment
- Animal models for the study of fetal tissue repair
- CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata
- Evidence for Masculinization of Adipokine Gene Expression in Visceral and Subcutaneous Adipose Tissue of Obese Women With Polycystic Ovary Syndrome (PCOS)
- Granulation Tissue that Developed after a Minor Trauma in a Psoriatic Patient on Long-term Etretinate Therapy
- Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis
- Platelet-Therapeutics to Improve Tissue Regeneration and Wound Healing—Physiological Background and Methods of Preparation
- APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex
- ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation